AVMXY News and Press, Avita Medical

Trading of American Depository Shares to begin under the ticker symbol “RCEL” on October 1st AVITA Medical (ASX: AVH, NASDAQ: RCEL), a regenerative medicine company with a technology platform positioned to address unmet medical needs in therapeutic skin restoration, annou...

On June 14, 2019, I published " The Stem Cell Triple Play: 3 Companies With Great Value Drivers ". Given how out of favor the stem cell sector has been for many years, I was surprised by the massive interest that this article generated. Given this unexpected level of interest and some co...

Autolus Therapeutics (NASDAQ: AUTL ) initiated with Buy rating and $26 (99% upside) price target at Needham. More news on: Autolus Therapeutics plc, Edwards Lifesciences Corporation, Elanco Animal Health Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...

Recent journal publications investigate the potential use of the RECELL System to treat multiple dermatological conditions AVITA Medical (ASX: AVH) (OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of innovative therapies leveraging the he...

First RECELL System clinical trial in the U.S. focused on acute soft tissue injuries, defects, and reconstruction; study expected to commence within next 6 months AVITA Medical (ASX: AVH, OTCQX: AVMXY), a regenerative medicine company focused on the development and commercialization of...

AVITA Medical (ASX: AVH, OTCQX: AVMXY), a global regenerative medicine company, acknowledges that the company will be added to the S&P/ASX 300 index, effective upon market open on 23 September 2019. “We are pleased to be included in the S&P/ASX 300 index, which is a reflect...

Active M&A Environment in Robotic Medical Device Segment Continues; Following J&J’s Acquisition of Auris Health for $5 Billion in February 2019, Stereotaxis’ Robotic Vascular Peer Corindus Vascular Robotics (CVRS) is being Acquired for $1.1 Billion by Siemens Healthin...

Australian small-cap medical device company, Avita Medical (ASX-AVH), is not exactly a black box. If you search hard enough, you can find helpful information. Its ADR trades in the US as AVMXY . It has been on my radar screen for less than a year based on the visceral appeal of its burn tre...

Total revenue of A$17.0 million for fiscal year 2019 (FY19), an increase of 50% year-over-year U.S. product sales of A$6.2 million for FY19 U.S. product sales of A$2.9 million for fourth quarter, an increase of 32% compared to FY third quarter sales AVITA Medical (ASX: ...

by Daniel Shvartsman The first half of 2019 saw a lot of green in the markets, as broader indices recovered from the brief bear market in the second half of 2018 and returned to new heights. Despite that, the wall of worry continued to grow, even if the specific concerns changed. Instead o...